Komori
Occurring Fact4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding a Change in the Largest Shareholder Among the Major Shareholders

Rohto Pharmaceutical is scheduled to acquire 2,866,900 of the Company's common shares. Its ownership ratio will rise from 3.19% to 11.46%, making it the largest shareholder. Accordingly, Kissei Pharmaceutical will no longer be the largest shareholder, moving from first to second place, while the Company states that there will be no impact on its business results.

Worth reading
51Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2866900
shares
Wording
Conditional
How definitive the wording is.

Change in largest shareholder, a major shareholder

Subject Entity

わかもと製薬株式会社の株主構成(ロート製薬株式会社、キッセイ薬品工業株式会社)

Occurrence2025年2月6日

(異動予定年月日)

This disclosure02/06/2025
Cause

ロート製薬株式会社が当社普通株式2,866,900株を取得すること(取得目的・理由はNot disclosed)

Change in voting rights ownership ratio

ロート製薬株式会社3.19%→11.46%(+8.27pt)
キッセイ薬品工業株式会社10.90%→10.90%(0.00pt)

The voting rights ownership percentage is the proportion of the voting rights exercisable at a shareholders' meeting held by the shareholder.

Voting rights ownership percentage before the change

ロート製薬株式会社:11,050個(1,105,000株)、3.19%、2024年9月30日現在。キッセイ薬品工業株式会社:37,780個(3,778,000株)、10.90%、2024年9月30日現在。

Voting rights ownership percentage after the change

ロート製薬株式会社:39,719個(3,971,900株)、11.46%、第1位。キッセイ薬品工業株式会社:37,780個(3,778,000株)、10.90%、第2位。

Impact on Earnings Forecast

The transaction will have no impact on the Company's financial results.

Outlook

今後もロート製薬株式会社とのさらなる持続的な提携を図り、製品とサービスの提供を通じて人々の健康に貢献する。具体的な時期の記載はない。なお、本件による当社業績への影響はない。

Event that occurred
ItemDetails
Event nameChange in largest shareholder, a major shareholder
Date of occurrence2025年2月6日(異動予定年月日)
Subject Entityわかもと製薬株式会社の株主構成(ロート製薬株式会社、キッセイ薬品工業株式会社)
Causeロート製薬株式会社が当社普通株式2,866,900株を取得すること(取得目的・理由はNot disclosed)
Impact on Earnings ForecastThe transaction will have no impact on the Company's financial results.
Voting rights ownership percentage before the changeロート製薬株式会社:11,050個(1,105,000株)、3.19%、2024年9月30日現在。キッセイ薬品工業株式会社:37,780個(3,778,000株)、10.90%、2024年9月30日現在。
Voting rights ownership percentage after the changeロート製薬株式会社:39,719個(3,971,900株)、11.46%、第1位。キッセイ薬品工業株式会社:37,780個(3,778,000株)、10.90%、第2位。
Outlook今後もロート製薬株式会社とのさらなる持続的な提携を図り、製品とサービスの提供を通じて人々の健康に貢献する。具体的な時期の記載はない。なお、本件による当社業績への影響はない。
Items this document does not state (17)
Date recognized / date notice receivedTarget Locations / ProductsAmount of Impact on Business PerformanceAccounting period in which recognizedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityPlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

ロート製薬から、2025年2月6日付で当社普通株式2,866,900株を取得する旨の報告を受けたため。取得の目的・背景は示されていない。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding a Change in the Largest Shareholder Among the Major Shareholders | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori